Clarity Pharmaceuticals (ASX: CU6) Secures Historic FDA Breakthrough Status as US$2 Billion Cancer Imaging Opportunity Takes Shape

Clarity Pharmaceuticals (ASX: CU6) has achieved a major regulatory milestone, becoming the first company to receive US Food and Drug Administration (FDA) Breakthrough Therapy designation for a PSMA PET prostate cancer imaging agent.

Announced on 12 November 2026, the recognition strengthens Clarity's pathway towards commercialisation after clinical studies demonstrated promising detection advantages over existing imaging technology.

With the US PSMA PET imaging market generating approximately US$2 billion annually, Clarity is positioning itself to compete in a substantial and expanding healthcare market.

Key Numbers

• 78% detection rate: Clarity's copper-64 SAR-bisPSMA identified suspected recurrent prostate cancer in 78% of participants, compared with 36% using gallium-68 PSMA-11 in the Phase II Co-PSMA study.
• 63 lesions detected: Next-day copper-64 imaging identified 63 lesions compared with 24 using the established comparator.
• US$2 billion: Estimated annual US PSMA PET imaging market sales, with Clarity forecasting market growth beyond US$3 billion by 2029.
• $152.9 million: Cash reserves at 30 September 2026.
• $23.1 million: Net operating cash outflow during the September 2026 quarter.

FDA Breakthrough Designation Opens a Stronger Commercial Pathway

The FDA granted Breakthrough Therapy designation to copper-64 SAR-bisPSMA for detecting PSMA-positive lesions in men with suspected recurrent prostate cancer.

The designation provides access to intensive FDA guidance, closer regulatory collaboration and potential eligibility for Priority Review.

This represents an important development for Clarity as it advances towards potential US regulatory approval.

The decision was supported by clinical evidence from the Phase II Co-PSMA study, Phase I/II COBRA trial and real-world observations.

In the 50-patient Co-PSMA study, Clarity's imaging technology achieved a 78% detection rate compared with 36% for gallium-68 PSMA-11.

Imaging findings also contributed to changes in planned patient management for 44% of participants.

These results highlight the technology's potential to improve clinical decision-making, particularly in patients where recurrent prostate cancer remains difficult to detect.

While Breakthrough Therapy designation does not constitute marketing approval, it provides meaningful regulatory recognition of the preliminary clinical evidence.

What Stands Out to Us

Clarity's competitive opportunity extends beyond improved imaging performance.

Its proprietary SAR technology securely binds radioactive copper isotopes, supporting both diagnostic imaging and targeted cancer therapy development.

Copper-64 has a half-life of approximately 12.7 hours, compared with one to two hours for commonly used alternatives.

This longer imaging window could support broader distribution, centralised manufacturing and improved patient access.

Clarity also holds composition-of-matter patent protection for SAR-bisPSMA until at least 2038, potentially reinforcing its competitive position.

Financially, the company enters this important development phase with substantial liquidity.

Its $152.9 million cash position represents approximately 6.6 quarters of funding at the September quarter's net operating cash outflow rate, although future expenditure may vary.

What the Company Is Doing Now

Clarity has successfully completed recruitment for its two registrational Phase III trials, AMPLIFY and CLARIFY.

Both studies are progressing through patient follow-up, with topline results anticipated during the first half of 2027.

The company is also advancing its SECuRE treatment program using copper-67 SAR-bisPSMA, expanding its potential beyond diagnostic imaging.

Alongside clinical development, Clarity is strengthening its manufacturing and commercial capabilities in preparation for a potential US market launch.

These activities support a broader strategy to establish a differentiated radiopharmaceutical platform across cancer diagnosis and treatment.

Insight: Could Clarity Become a Significant Player in Cancer Imaging?

We believe Clarity's latest FDA milestone substantially strengthens its commercial prospects and reinforces the potential value of its proprietary imaging platform. The encouraging head-to-head clinical results, patent protection and strong cash reserves provide a credible foundation for future growth. Particularly attractive is the combination of potential diagnostic advantages and access to an established multibillion-dollar market. However, meaningful product revenue remains dependent on regulatory approval and successful commercial execution. The upcoming Phase III results will be critical in determining whether Clarity can translate its promising technology into sustainable commercial value.

What Happens Next?

The next major catalysts are topline results from the AMPLIFY and CLARIFY Phase III trials, expected in the first half of 2027.

Positive outcomes could strengthen the company's regulatory submissions and support its preparations for commercialisation.

Market participants will also be watching manufacturing readiness, future cash expenditure and progress towards establishing commercial distribution.

For Clarity, the FDA's Breakthrough Therapy designation represents an important step towards bringing its next-generation prostate cancer imaging technology to market.

With encouraging clinical evidence, substantial funding and two pivotal trials approaching their next milestones, the company has established a promising foundation for its next stage of development.